Interpretation of Surrogate Endpoints in the Era of the 21st Century Cures Act

BMJ. 2016 Dec 30;355:i6286. doi: 10.1136/bmj.i6286.

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers*
  • Clinical Trials as Topic / legislation & jurisprudence*
  • Clinical Trials as Topic / standards
  • Disease-Free Survival
  • Drug Approval / legislation & jurisprudence*
  • Humans
  • Neoplasms / drug therapy*
  • Quality of Life*
  • Survival Rate*
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents
  • Biomarkers